liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
Rudolfstiftung Hospital Vienna, Austria.
Hospital University of Valme, Spain.
GWT TUD GmbH, Germany.
Oslo University Hospital, Norway.
Show others and affiliations
2015 (English)In: Diabetes, obesity and metabolism, ISSN 1462-8902, E-ISSN 1463-1326, Vol. 17, no 7, 630-638 p.Article in journal (Refereed) Published
Abstract [en]

Aims: To assess the efficacy and safety of adjunctive saxagliptin vs glimepiride in elderly patients with type 2 diabetes (T2D) and inadequate glycaemic control. Methods: In this multinational, randomized, double-blind, phase IIIb/IV study (GENERATION; NCT01006603), patients aged greater than= 65 years were randomized (1:1) to receive saxagliptin 5 mg/day or glimepiride less than= 6 mg/day, added to metformin, during a 52-week treatment period. The primary endpoint was achievement of glycated haemoglobin (HbA1c) less than7.0% at week 52 without confirmed/severe hypoglycaemia. The key secondary endpoint was incidence of confirmed/severe hypoglycaemia. Safety and tolerability were also assessed. Results: Of 720 patients randomized (360 in each treatment group; mean age 72.6 years; mean T2D duration 7.6 years), 574 (79.8%) completed the study (saxagliptin 80.3%; glimepiride 79.2%). Similar proportions of patients achieved the primary endpoint with saxagliptin and glimepiride (37.9 vs 38.2%; odds ratio 0.99, 95% confidence interval 0.73, 1.34; p=0.9415); however, a significant treatment-by-age interaction effect was detected (p=0.0389): saxagliptin was numerically (but not significantly) superior to glimepiride for patients aged less than75 years (39.2 vs 33.3%) and numerically inferior for patients aged greater than= 75 years (35.9 vs 45.5%). The incidence of confirmed/severe hypoglycaemia was lower with saxagliptin vs glimepiride (1.1 vs 15.3%; nominal pless than0.0001). Saxagliptin was generally well tolerated, with similar incidences of adverse events compared with glimepiride. Conclusion: As avoiding hypoglycaemia is a key clinical objective in elderly patients, saxagliptin is a suitable alternative to glimepiride in patients with T2D aged greater than= 65 years.

Place, publisher, year, edition, pages
Wiley , 2015. Vol. 17, no 7, 630-638 p.
Keyword [en]
dipeptidyl peptidase-4 inhibitor; randomized trial; sulphonylureas; type 2 diabetes
National Category
Basic Medicine
Identifiers
URN: urn:nbn:se:liu:diva-120138DOI: 10.1111/dom.12461ISI: 000356592200004PubMedID: 25761977OAI: oai:DiVA.org:liu-120138DiVA: diva2:841634
Note

Funding Agencies|AstraZeneca; Bristol-Myers Squibb

Available from: 2015-07-14 Created: 2015-07-13 Last updated: 2015-07-14

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Östgren, Carl Johan
By organisation
Division of Community MedicineFaculty of Medicine and Health Sciences"Primary Health Care in Motala"
In the same journal
Diabetes, obesity and metabolism
Basic Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 47 hits
ReferencesLink to record
Permanent link

Direct link